CLAIMS

What is claimed:

1. A ophthalmic ~~composition~~ emulsion comprising an active ingredient, the active ingredient consisting of a physiologically effective amount of ~~an androgen~~ testosterone, and a lipophilic vehicle wherein said ~~composition~~ emulsion is suitable for topical administration to an eye.

~~2. The composition of claim 1, wherein the androgen is selected from the group consisting of testosterone, dihydrotestosterone, dehydroepiandrosterone, androstenedione, androstenediol, androsterone, oxymetholone, and 17α-methyl-nortestosterone, methyltestosterone, 7-methyl-nortestosterone, and esters, analogues, and combinations thereof.~~

~~3. The composition of claim 1 wherein the androgen is testosterone.~~

42. The ~~composition~~ emulsion of claim 1 wherein testosterone is present in the composition from ~~about~~ 0.01 w/w % to ~~about~~ 0.10 w/w%.

53. The ~~composition~~ emulsion of claim 1 wherein testosterone is present in the composition from ~~about~~ 0.01 w/w % to ~~about~~ 0.05 w/w%.

~~6. The composition of claim 1 wherein testosterone is present in the composition from about 0.01 w/w % to about 0.05 w/w%.~~

~~7. The composition of claim 1, wherein the composition is selected from the group consisting of a solution, emulsion, suspension, gel, ointment, occlusive film, and a sustained release film.~~

84. The ~~composition~~ emulsion of claim 1, wherein the composition comprises an additional constituent selected from the group consisting of a thickener, neutralizing agent,

emulsifier, ~~lipophilic vehicle,~~ buffering agent, tonicity agent, demulcent, preservative, plasticizer, occlusive agent, film former, and a combination thereof.

~~9~~5. The ~~composition~~ emulsion of claim 1, further comprising an agent selected from the group consisting of an anti-inflammatory, antimicrobial, analgesic, anesthetic, lubricating agent, and a combination thereof.

~~10~~6. The ~~composition~~ emulsion of claim 1, further comprising a solubility enhancing agent.

~~11. Use of an ophthalmic composition comprising a physiologically effective amount of an androgen in the manufacture of a medicament for treating an ocular condition resulting from an androgen deficiency, wherein said medicament is suitable for topical administration to an eye, and wherein at least one symptom of the ocular condition is alleviated.~~

~~12. The use of claim 11, wherein the ocular condition is blepharitis.~~

~~13. The use of claim 11, wherein the androgen is selected from the group consisting of testosterone, dihydrotestosterone, dehydroepiandrosterone, androstenedione, androstenediol, androsterone, oxymetholone, and 17α-methyl-nortestosterone, methyltestosterone, 6-methyl-nortestosterone, and esters, analogues, and combinations thereof.~~

~~14. The use of claim 11, wherein the medicament is selected from the group consisting of a solution, emulsion, suspension, gel, ointment, occlusive film, and a sustained release film.~~

~~15. The use of claim 11, wherein the medicament comprises an additional constituent selected from the group consisting of a thickener, neutralizing agent,~~

emulsifier, lipophilic vehicle, buffering agent, tonicity agent, demulcent, preservative, plasticizer, occlusive agent, film former, and a combination thereof.

16. The use of claim 11, further comprising an agent selected from the group consisting of an anti-inflammatory, antibiotic, analgesic, anesthetic, lubricating agent, soothing agent, and a combination thereof.

17. The use of claim 11, wherein symptoms associated with the ocular condition are prevented.

18. The use of claim 11, wherein symptoms associated with the ocular condition are reduced.

19. The use of claim 11, wherein symptoms associated with the ocular condition are eliminated.

20. The use of claim 11, wherein the administration is to be repeated until one or more symptoms of the ocular condition are reduced.

21. The use of claim 11, wherein the administration is to be repeated until one or more symptoms of the ocular condition are eliminated.

22. The use of claim 11, wherein the medicament is to be administered to the eye, upper lid, lower lid, and a combination thereof.

7. The emulsion of claim 1, wherein the lipophilic vehicle is selected from the group consisting of castor oil, squalane, diethylene glycol monoethyl ether, isostearyl isostearate, isopropyl myristate, propylene glycol, mineral oil, silicone oil, cetyl alcohol, and stearyl alcohol.

8. The emulsion of claim 7, wherein the lipophilic vehicle is castor oil.

9. The emulsion of claim 1 wherein testosterone is present in the composition from 0.01 w/w % to 0.30 w/w%.

10. The emulsion of claim 9 wherein the lipophilic vehicle is present in the composition in an amount of 0.25 w/w %.